Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Patient Satisfaction
研究概览
简要总结
Maternal diabetes in pregnancy can negatively impact fetal well-being and contribute to adverse pregnancy outcomes. Much of the morbidity associated with diabetes in pregnancy can be minimized with tight glucose control. A number of studies in non-pregnant populations have highlighted the feasibility, acceptability and efficacy of text messaging interventions for improving diabetic compliance and control. This study will investigate whether a text messaging intervention is feasible and effective in an urban, diabetic, obstetric clinic and whether this intervention can improve compliance with diabetes care, glucose control and pregnancy outcomes. The study will also assess satisfaction with the intervention itself.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pregnant women aged 18-50 years
- •Planned delivery at Hospital of the University of Pennsylvania
排除标准
- •Gestational age greater than 34 weeks at initial visit in the Penn Perinatal Diabetes Program
- •Women who are unable to read English as all text messages will be in English
- •Women who do not have a cellular phone capable of receiving text messages as this is the study intervention
结局指标
主要结局
Patient Satisfaction
时间窗: date of enrollment up to 12 weeks post partum
Patient satisfaction with the texting intervention as measured by a post-study survey
Compliance with Obstetric and Diabetes Care
时间窗: OB screening visit through 12 weeks postpartum
Proportion of prenatal visits attended, proportion of assigned blood glucose logs sent to clinic for review, proportion of assigned blood glucose values checked, compliance with attendance at postpartum visit.
次要结局
- Efficacy measures(Diabetes diagnosis through 12 weeks postpartum)
- Maternal Outcomes(Delivery date through 12 weeks postpartum)
- Healthcare Utilization Measures(Screening OB visit through 12 weeks postpartum)
- Neonatal Outcomes(Neonate delivery through 12 weeks postpartum)
研究者
Celeste Durnwald
Assistant Professor, Maternal Fetal Medicine, Department of Obstetrics and Gynecology Director, Penn Perinatal Diabetes Program Director, High Risk Clinic at the Helen O. Dickens Center for Women's Health
University of Pennsylvania